InsiderSignal.AI

InsiderSignal.ai

PTCT - Ptc Therapeutics, Inc.

Insider Sale by Pauwels Eric (CHIEF BUSINESS OFFICER)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Pauwels Eric, serving as CHIEF BUSINESS OFFICER at Ptc Therapeutics, Inc. (PTCT), sold 3,019 shares at $69.36 per share, for a total transaction value of $209,398.00. Following this transaction, Pauwels Eric now holds 77,122 shares of PTCT.

This sale represents a 4.00% decrease in Pauwels Eric's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, February 18, 2026 and publicly disclosed via SEC Form 4 filing on Friday, February 20, 2026, 2 days after the trade was made.

Ptc Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Pauwels Eric

Pauwels Eric

CHIEF BUSINESS OFFICER

# Eric Pauwels Eric Pauwels is the Chief Business Officer at PTC Therapeutics, Inc. (PTCT), a role he has held since 2020. He joined the company in March 2015 as Senior Vice President and General Manager of the Americas, leading global P&L business operations including sales, marketing, commercial strategy, market access, and medical affairs worldwide.[[1]](https://www.ptcbio.com/team/leadership/eric-pauwels/)[[2]](https://theorg.com/org/ptc-therapeutics/org-chart/eric-pauwels) With over 40 years of experience in healthcare, particularly in rare diseases, he has launched more than 30 biopharmaceutical products globally, including 11 in areas like lysosomal storage diseases, Duchenne muscular dystrophy, and other genetic disorders.[[1]](https://www.ptcbio.com/team/leadership/eric-pauwels/) Prior to PTC, Pauwels served as Chief Commercial Officer and President of International at NPS Pharmaceuticals (2011-2015) and as the first Chief Commercial Officer for Shire Human Genetic Therapies Rare Disease Business (2005-2010) following the acquisition of TKT.[[1]](https://www.ptcbio.com/team/leadership/eric-pauwels/) He previously held vice president and general management roles at Bayer Healthcare Pharmaceuticals, Fournier Pharma, and Johnson & Johnson across the USA, China, France, and Belgium.[[1]](https://www.ptcbio.com/team/leadership/eric-pauwels/) Eric earned a Bachelor of Science from California State Polytechnic University in Pomona, California.[[1]](https://www.ptcbio.com/team/leadership/eric-pauwels/) Recently, as a 10% owner, he sold 43,492 shares for approximately $3.28 million under a Rule 10b5-1 plan in December 2025.[[4]](https://longbridge.com/en/news/270359958)

View full insider profile →

Trade Price

$69.36

Quantity

3,019

Total Value

$209,398.00

Shares Owned

77,122

Trade Date

Wednesday, February 18, 2026

3 days ago

SEC Filing Date

Friday, February 20, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Ptc Therapeutics, Inc.

Company Overview

No company information available
View news mentioning PTCT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4154559

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime